They are guaranteed to have already been in discussions with the FDA. Moonshot hoping they are reviewing India data (whatever that might be) and reconciling the protocols used with the MAYO clinic proposal.
What I am concerned about is the quality of information from the trial, and how it is going to translate. The company leaving us in the dark about the results thus far, other than the one interview, is a little bit puzzling to me.
Market Data 
Markets 
